Mark David Hylarides

US Patent:

6358710, Mar 19, 2002

Filed:

Jun 9, 1997

Appl. No.:

08/871488

Inventors:

Scott S. Graves - Monroe WA
John M. Reno - Brier WA
Robert W. Mallett - Everett WA
Mark D. Hylarides - Stanwood WA
Stephen M. J. Searle - Cambridge, GB
Andrew H. Henry - Ely, GB
Jan T. Pedersen - Bronshoj, DK
Anthony R. Rees - St. Chaptes, GB

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

C12P 2104

US Classification:

435 701, 435325, 435330, 5303871, 4241301, 436547

Abstract:

Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.

US Patent:

6767531, Jul 27, 2004

Filed:

Dec 11, 2001

Appl. No.:

10/014335

Inventors:

Alan R. Fritzberg - Olga WA
Paul G. Abrams - Seattle WA
Lauren Marie Tatalick - Redmond WA
Kent R. Thoelke - Seattle WA
James Kyle Bryan - Seattle WA
Mark D. Hylarides - Stanwood WA
Elizabeth K. John - San Diego WA

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

A61K 5100

US Classification:

424 165, 424 111, 534 15

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7070759, Jul 4, 2006

Filed:

Jan 24, 2005

Appl. No.:

11/041828

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

A61K 51/00
A61M 36/14

US Classification:

424 165, 424 91, 424 111, 534 15, 514836

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7097823, Aug 29, 2006

Filed:

Feb 23, 2004

Appl. No.:

10/784476

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

NEORX Corporation - Seattle WA

International Classification:

A61K 51/00
A61M 36/14

US Classification:

424 165, 424 111, 424 91, 534 15

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7378077, May 27, 2008

Filed:

Jul 12, 2006

Appl. No.:

11/485183

Inventors:

Alan R. Fritzberg - Olga WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

Poniard Pharmaceuticals, Inc. - Seattle WA

International Classification:

A61K 51/00
A61M 36/14

US Classification:

424 165, 424 111, 424 91, 514492, 514836, 534 15

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7408046, Aug 5, 2008

Filed:

Jun 30, 2004

Appl. No.:

10/882054

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

Poniard Pharmaceuticals, Inc. - Seattle WA

International Classification:

C07F 5/00

US Classification:

534 15, 424 111, 424 165, 424 91

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

7696331, Apr 13, 2010

Filed:

Jun 19, 2008

Appl. No.:

12/142664

Inventors:

Alan R. Fritzberg - Olga WA, US
Paul G. Abrams - Seattle WA, US
Lauren Marie Tatalick - Redmond WA, US
Kent R. Thoelke - Seattle WA, US
James Kyle Bryan - Seattle WA, US
Mark D. Hylarides - Stanwood WA, US
Elizabeth K. John - San Diego CA, US

Assignee:

Poniard Pharmaceuticals, Inc. - Seattle WA

International Classification:

C07F 5/00

US Classification:

534 15, 424 111, 424 165, 424 91

Abstract:

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

US Patent:

20030119078, Jun 26, 2003

Filed:

Jan 24, 2002

Appl. No.:

10/056794

Inventors:

Scott Graves - Monroe WA, US
John Reno - Brier WA, US
Robert Mallett - Everett WA, US
Mark Hylarides - Stanwood WA, US
Stephen Searle - Cambridge, GB
Andrew Henry - Ely, GB
Jan Pedersen - Bronshoj, DK
Anthony Rees - St. Chaptes, FR

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

G01N033/574
C07K016/44

US Classification:

435/007230, 530/388150

Abstract:

Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.